COMP <GO>
BVS vs LLY // EV/EBITDA & P/E VALUATION
Bioventus Inc. (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BVS 2
— LLY 11
▲ EV/EBITDA & P/E VALUATION LEADER: BVS
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
valuation
26.3x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 83.64% | -15.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | 32.36% | -21.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 26.3x | 36.4x | -10.12 | BVS | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 2.30% | +3.47 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | 40.21% | -30.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 31.90% | -27.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 45.51% | -46.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 9.29 | -7.04 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.9 | 66.6 | -22.66 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 26.3x | +24.95 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.25B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | LLY REV | BVS GROSS % | LLY GROSS % | BVS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $65.18B | 68.3% | 83.0% | $72.1M | $16.81B |
| FY 2024 | $573.3M | $45.04B | 67.7% | 81.3% | $37.8M | $8.82B |
| FY 2023 | $512.3M | $34.12B | — | 79.3% | $15.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
LLY // BETA 0.51